Co- occurring HER2 and PD-L1 expression in patients with HER2-positive trastuzumab-refractory gastric cancer (GC)/gastroesophageal junction adenocarcinoma (GEJA): Biomarker analysis from the trastuzumab deruxtecan (T-DXd) DESTINY-Gastric03 trial

Y. Janjigian; S. Rha; D. Oh; M. Díez García; H. van Laarhoven; Y. Chao; M. Di Bartolomeo; N. Haj Mohammad; W. Zhong; E. Croydon; F. Cecchi; J. Lee

doi:10.1016/j.annonc.2022.04.406

YUHSpace

BROWSE

0 158

Cited 0 times in

Co- occurring HER2 and PD-L1 expression in patients with HER2-positive trastuzumab-refractory gastric cancer (GC)/gastroesophageal junction adenocarcinoma (GEJA): Biomarker analysis from the trastuzumab deruxtecan (T-DXd) DESTINY-Gastric03 trial

Authors: Y. Janjigian ; S. Rha ; D. Oh ; M. Díez García ; H. van Laarhoven ; Y. Chao ; M. Di Bartolomeo ; N. Haj Mohammad ; W. Zhong ; E. Croydon ; F. Cecchi ; J. Lee